RxDoctor Payments DataLook up a doctor →

Yoshihiro Yonekawa, MD

Ophthalmology · Plymouth Meeting, PANPI 1962727008

Payments from drug & device makers

$915,600in general payments, 2019–2025

Across 320 payments — averaging $2861.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$310K
  • Genentech, Inc.$235K
  • Regeneron$207K
  • Bayer$74K
  • Alcon$60K
  • F. Hoffmann-la Roche AG$9K
  • plus $21K from 10 others
$12,383in research payments, 2019–2025

Across 11 payments — averaging $1125.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$12K

What the payments were for

  • Consulting fees$87,82792%
  • Speaking & faculty fees$7501%
  • Travel & lodging$3,6864%
  • Food & beverage$2,7473%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$915,600 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,855,044
Medicare patients
1,524
Services billed
57,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate178$8,748
Bromfenac Sodium35$4,770
Loteprednol Etabonate12$3,308
Ketorolac Tromethamine47$1,360
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$549
Ofloxacin32$482
Atropine Sulfate15$464
Dorzolamide Hcl16$171
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim17$153
Brimonidine Tartrate20$104

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →